IFNA1 and autoimmune polyendocrine syndrome type 1: Intriguingly, while neutralizing IFN-AABs in patients with autoimmune polyendocrine syndrome type 1 (APS-1) can associate with a severe course of SARS-CoV-2 infection [13–17], their mere presence does not inevitably lead to severe disease [18].